Invasive fungal infections in critically ill COVID-19 patients in a large tertiary university hospital in Israel.


Journal

Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 11 2021
revised: 31 01 2022
accepted: 31 01 2022
pubmed: 14 2 2022
medline: 4 5 2022
entrez: 13 2 2022
Statut: ppublish

Résumé

An increasing number of studies have tried to determine the incidence of invasive fungal infections (IFIs) in COVID-19 patients. Challenges in the diagnosis of pulmonary aspergillosis in these patients have led to new definitions of COVID-19-associated pulmonary aspergillosis (CAPA). The aim of this study was to determine the incidence and outcomes of and risk factors for IFIs in critically-ill COVID-19 patients, using the new definitions, in a tertiary center in Israel. A case-controlled study (from 1 September 2020 to 31 March 2021) in which data from COVID-19 critically-ill patients with a diagnosis of IFI were collected and compared to a control group without IFI. The incidence of IFI amongst 311 COVID-19 critically-ill patients was 6.1%. 3.5% had CAPA and 3.5% had candidemia. In-hospital mortality was higher amongst patients with IFI compared to those without IFI (89.4% vs 60%, p < 0.03). The most significant predictors of IFI were cardiovascular co-morbidity and carbapenem use. The low incidence of CAPA in our group of COVID-19 critically-ill patients was consistent with recent reports, underscoring the importance of differentiating between true infection and colonization. Awareness and timely diagnosis of IFIs in COVID-19 critically-ill patients are imperative considering the associated high mortality.

Identifiants

pubmed: 35152143
pii: S0883-9441(22)00030-2
doi: 10.1016/j.jcrc.2022.154004
pmc: PMC8830264
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

154004

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare none.

Références

Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Otolaryngol. 2021 Nov-Dec;42(6):103080
pubmed: 34022619
Respiration. 2011;81(3):229-35
pubmed: 21358222
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Am J Respir Crit Care Med. 2017 Apr 7;196(4):524-527
pubmed: 28387526
Intensive Care Med. 2014 Sep;40(9):1303-12
pubmed: 25097069
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
J Clin Microbiol. 2021 Sep 20;59(10):e0113521
pubmed: 34288730
Am J Respir Crit Care Med. 2021 Feb 1;203(3):307-317
pubmed: 33480831
J Chemother. 1999 Oct;11(5):385-90
pubmed: 10632385
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
PLoS One. 2021 May 6;16(5):e0251170
pubmed: 33956882
J Fungi (Basel). 2020 Nov 13;6(4):
pubmed: 33203016
Clin Infect Dis. 2021 Oct 5;73(7):e1645-e1648
pubmed: 32887998
Front Med (Lausanne). 2020 Dec 17;7:606976
pubmed: 33392229
Lancet. 2003 Nov 29;362(9398):1828-38
pubmed: 14654323
J Clin Microbiol. 2021 Nov 18;59(12):e0122921
pubmed: 34495710
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
J Clin Microbiol. 2017 Jul;55(7):2153-2161
pubmed: 28446576
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Clin Microbiol Infect. 2022 Apr;28(4):580-587
pubmed: 34454093
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Clin Infect Dis. 2021 Nov 2;73(9):e2838-e2839
pubmed: 33124650
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
Mycoses. 2021 Feb;64(2):152-156
pubmed: 33275821
Mycoses. 2021 Sep;64(9):1083-1091
pubmed: 34085319
Front Cell Infect Microbiol. 2019 Oct 11;9:352
pubmed: 31681629
J Microbiol Immunol Infect. 2021 Feb;54(1):46-53
pubmed: 33012653
Clin Infect Dis. 2020 Oct 23;71(7):1760-1763
pubmed: 31905235
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Expert Rev Respir Med. 2015 Feb;9(1):89-96
pubmed: 25547335
J Intensive Care Med. 2020 Jun;35(6):542-553
pubmed: 29628014
Am J Respir Crit Care Med. 2020 Sep 15;202(6):902-903
pubmed: 32687389
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644
pubmed: 32860682
Med Mycol. 2011 Feb;49(2):113-20
pubmed: 20818922
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146
pubmed: 34192610
N Engl J Med. 2015 Oct 8;373(15):1445-56
pubmed: 26444731
Infection. 2022 Feb;50(1):43-56
pubmed: 34570355
J Mycol Med. 2020 Jun;30(2):100971
pubmed: 32307254
Crit Care Med. 2020 Sep;48(9):e799-e804
pubmed: 32452888
Intensive Care Med. 2020 Sep;46(9):1787-1789
pubmed: 32661615

Auteurs

Oshrat Ayalon (O)

Faculty of Medicine, Hebrew University of Jerusalem, Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel.

Matan J Cohen (MJ)

Clalit Health Services, Jerusalem District, affiliated with the Hebrew University Hadassah Medical School, Jerusalem, Israel.

Efrat Orenbuch-Harroch (E)

Faculty of Medicine, Hebrew University of Jerusalem, Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Medical Intensive Care Unit, Hadassah Medical Center, Jerusalem, Israel.

Sigal Sviri (S)

Faculty of Medicine, Hebrew University of Jerusalem, Medical Intensive Care Unit, Hadassah Medical Center, Jerusalem, Israel.

Peter Vernon van Heerden (PV)

Faculty of Medicine, Hebrew University of Jerusalem, General Intensive Care Unit, Hadassah Medical Center, Jerusalem, Israel.

Maya Korem (M)

Faculty of Medicine, Hebrew University of Jerusalem, Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel. Electronic address: mayak@hadassah.org.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH